Loading clinical trials...
Loading clinical trials...
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
UCB Pharma
NCT07526350 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, and more
NCT06875960 · Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
NCT06335979 · Systemic Lupus Erythematosus, SLE
NCT06647069 · Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)
NCT07371468 · Systemic Lupus Erythematosus
Birmingham, Alabama
Tucson, Arizona
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions